Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
Ethos Technologies Inc. reports developments tied to its digital life insurance platform, which connects consumers, independent agents and insurance carriers through online underwriting and policy issuance tools. The company distributes life insurance products in direct-to-consumer and third-party channels and earns carrier commissions and administrator-service revenue from activated policies.
Recurring updates include quarterly results, direct and third-party channel revenue, policy activation trends, and technology integrations that expand digital purchasing. Company announcements also cover carrier collaborations and product additions, including whole life, final expense, and indexed universal life offerings delivered through Ethos' platform.
aTyr Pharma (Nasdaq: LIFE) announced its participation in the NIH Rare Disease Day virtual conference on February 28, 2022, at 2:55pm EST. Sanjay S. Shukla, M.D., CEO, will join a panel discussing strategies for clinical trial recruitment, emphasizing lessons learned from the Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis during the pandemic. The event features industry leaders advocating for rare diseases awareness. aTyr is currently developing efzofitimod for severe inflammatory lung diseases, with a registrational trial expected to start this year.
aTyr Pharma (Nasdaq: LIFE) announced that its President and CEO, Sanjay S. Shukla, will present a corporate overview at the BIO CEO & Investor Conference from February 14 to 17, 2022, at the Marriott Marquis, New York.
The presentation is scheduled for February 15, 2022, at 1:15 p.m. EST. Additionally, aTyr management will engage in both in-person and virtual one-on-one meetings during the conference. More information about aTyr's innovative biotherapeutics focusing on tRNA synthetases can be found at www.atyrpharma.com.
aTyr Pharma has announced the nonproprietary name efzofitimod for its drug ATYR1923, which is under clinical development for pulmonary sarcoidosis. The company aims to initiate a registrational trial in 2022. Efzofitimod, an immunomodulator targeting neuropilin-2, is engineered from a splice variant of histidyl-tRNA synthetase and is viewed as a potential treatment for severe inflammatory lung diseases. Initial Phase 1b/2a clinical trials showed promising safety and efficacy, including improvements in lung function and reduced steroid use.
aTyr Pharma (Nasdaq: LIFE) announced that the FDA granted orphan drug designation for its candidate ATYR1923, aimed at treating pulmonary sarcoidosis, a chronic inflammatory disease affecting nearly 200,000 patients in the U.S. This milestone is significant as ATYR1923 may offer a transformative alternative to current treatments that are often limited and come with severe side effects. The company expects to begin a registrational trial this year after establishing clinical proof-of-concept in a recent Phase 1b/2a study.
aTyr Pharma (Nasdaq: LIFE), a company focused on innovative biotherapeutics, announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand for registered attendees starting January 10, 2022, at 7:00 am ET, and can also be accessed on the company’s website for 90 days post-event. aTyr’s primary product candidate, ATYR1923, targets inflammatory lung diseases.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced the appointment of Danielle Campbell as Vice President of Human Resources. Campbell will lead HR strategies, focusing on organizational development and talent management, as the company aims for growth and advanced clinical trials for its lead candidate, ATYR1923. CEO Sanjay Shukla emphasized her relevant experience as beneficial for the company's transition. Campbell has 15 years in biotech HR roles and received a stock option grant of 70,000 shares at $7.77 each, vesting over four years.
aTyr Pharma (Nasdaq: LIFE) announced a novel approach to generating new antibody candidates at the Antibody Engineering & Therapeutics Conference from December 12-16, 2021. Their presentation will highlight the practical utility of repertoire data for antibody affinity maturation, enhancing existing methods with minimal effort. This technique complements their tRNA synthetase platform, which focuses on creating biologics to modulate novel biological pathways. The workshop will be presented by Senior Scientist Luke Burman on December 12 at 11:15 AM PST.
aTyr Pharma (Nasdaq: LIFE) announced a manufacturing agreement with FUJIFILM Diosynth Biotechnologies for ATYR1923, its lead candidate for pulmonary sarcoidosis. The partnership aims to support the development and scale-up of ATYR1923, including bulk drug substance production for upcoming clinical trials. This collaboration is critical as aTyr prepares for late-stage clinical development and a potential Biologics License Application. The agreement underscores aTyr's commitment to delivering innovative treatments for inflammatory lung diseases.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced that President and CEO Sanjay S. Shukla will present at two virtual investor conferences in November 2021. The first event is the Stifel 2021 Virtual Healthcare Conference on November 17 at 4:40 PM EST. The second is the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 at 10:00 AM EST. Management will also participate in one-on-one meetings with registered investors. Replay options will be available on the company’s website following the events.
aTyr Pharma reported positive results from the Phase 1b/2a clinical trial of ATYR1923 for pulmonary sarcoidosis, providing proof-of-concept for its tRNA synthetase biology platform. The registrational trial is expected to begin in 2022. The company raised $80 million in a common stock offering in September 2021. Q3 2021 results showed cash reserves of $116.4 million, with R&D expenses at $5.1 million. No serious adverse events were reported in the study, and improvements in lung function and symptom measures were observed.